• Turnover: +10.88% to €214.07 million.
o Strong growth supported by Ségur and managed with a constant deployment effort.
o Significant increase in the contribution of “non-pharmacy” growth drivers to the Equasens Group’s 2022 turnover.
• High profitability and a solid balance sheet with a significant level of cash which gives the Group significant leeway in terms of borrowing capacity.
o Current Operating Income: +12.57% to €56.79 million.
o Net income: +18.35% to €48.70 million.
o Basic Earnings per Share: +18.52% to €3.09.
o CIF: +17.07% to €62.05 million.
• Dividend proposed for the 2022 financial year: €1.15 per share (+9.52%).
• Outlook for 2023: the Group’s financial solidity (no net debt and positive net cash of €56.26 million) enables it to maintain its ambitions for expansion in Europe and development in other areas of health.
The full press release is online at www.equasens.com
Investors section / Press releases
Listed on Euronext Paris™ – Compartment A
Included in Euronext Tech Leaders and European Rising Tech Label
Indices: MSCI GLOBAL SMALL CAP – GAÏA Index 2020 – CAC® SMALL and CAC® All-Tradable by inclusion
Eligible for the Deferred Settlement Service (SRD) and the PEA-PME scheme
ISIN: FR0012882389 – Mnemonic code EQS